Global Gastrointestinal Stromal Tumor (GIST) Drug Market By Product Type (Amcasertib, Anagrelide hydrochloride CR) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

According to Apex Market Research the Gastrointestinal Stromal Tumor (GIST) Drug market was valued at USD xx.xx million in 2019 and is anticipated to grow at a CAGR of xx% during the forecast period from 2020 to 2028. The report on Gastrointestinal Stromal Tumor (GIST) Drug market delivers detailed analysis covering major regional trends, market dynamics, and offer country-level market value of Gastrointestinal Stromal Tumor (GIST) Drug industry. Some of the major aspects considered during the course of research comprises definition of the product, classification of the product, industry structure, different participants in the Gastrointestinal Stromal Tumor (GIST) Drug ecosystem, etc. The report comprises of market value and forecast for the period from 2020 to 2028, CAGR measured for individual segment and regional market, competitive landscape of key market players, and profiling of major providers participating in the Gastrointestinal Stromal Tumor (GIST) Drug market.

The following manufacturers are covered in this report:
  • Ariad Pharmaceuticals, Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Boston Biomedical, Inc.
  • Calithera Biosciences, Inc.
  • Chipscreen Biosciences Ltd
  • Deciphera Pharmaceuticals, LLC
  • F. Hoffmann-La Roche Ltd.
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kolltan Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Omeros Corporation

The report estimates on the Gastrointestinal Stromal Tumor (GIST) Drug market economy trend, market numbers (Mn/Bn USD) and CAGR from the 2020-2028, considering 2019 as the base year. A global Gastrointestinal Stromal Tumor (GIST) Drug market report consist of all leading industry players, Gastrointestinal Stromal Tumor (GIST) Drug business sections, company profile, revenue supply by Gastrointestinal Stromal Tumor (GIST) Drug industry sections, global Gastrointestinal Stromal Tumor (GIST) Drug market trends, acquisitions and arrangements, contact info, recent development, geographic examination and even more using the assistance.

Since the onset of COVID-19 in December 2019, the governments of various countries declared lockdown and as result numerous economies around the world experienced severe economic downturn. Since early 2020, the Gastrointestinal Stromal Tumor (GIST) Drug market witnessed the impact of COVID-19 The report objects to provide pre-COVID-19 state of the Gastrointestinal Stromal Tumor (GIST) Drug market in years 2020 and 2019 and moreover it offers forecast for the Covid-19 period from 2020 to 2028.The report provides COVID-19 impact on Gastrointestinal Stromal Tumor (GIST) Drug market, global analysis, different challenges or threats and opportunities for stakeholders involved in the Gastrointestinal Stromal Tumor (GIST) Drug market.

Report Opportunity: Global Gastrointestinal Stromal Tumor (GIST) Drug Market

This report delivers an analytical examination of the Gastrointestinal Stromal Tumor (GIST) Drug market summarized in broad sections such as
  1. Gastrointestinal Stromal Tumor (GIST) Drug Market Summary
  2. Key Commercial Growths in the Gastrointestinal Stromal Tumor (GIST) Drug Industry
  3. Market Dynamics Affecting the Gastrointestinal Stromal Tumor (GIST) Drug Industry
  4. Important Market Trends and Future Development Scenario of the Gastrointestinal Stromal Tumor (GIST) Drug Market
  5. Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast, by Type, 2018 – 2028
  6. Competitive Landscape of Gastrointestinal Stromal Tumor (GIST) Drug Industry
  7. Positioning of Main Market Players in the Gastrointestinal Stromal Tumor (GIST) Drug Industry
  8. Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast, by Application, 2018 - 2028
  9. Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast, by End-use, 2018 - 2028
  10. Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast, by Geography, 2018 - 2028
Gastrointestinal Stromal Tumor (GIST) Drug Market Segmentation:

The report provides detailed examination of the Gastrointestinal Stromal Tumor (GIST) Drug market on the basis of various segments such as type, application and end-use industry. The Gastrointestinal Stromal Tumor (GIST) Drug market is segmented as follows:

Gastrointestinal Stromal Tumor (GIST) Drug Market, by Type:
  • Amcasertib
  • Anagrelide hydrochloride CR
  • APG-1351
  • Binimetinib
  • Others
Gastrointestinal Stromal Tumor (GIST) Drug Market, by Application:
  • Clinic
  • Hospital
  • Others
Geographic Coverage

The report on the Gastrointestinal Stromal Tumor (GIST) Drug market delivers an in depth country-level cross-sectional analysis across different regions around the globe. The report comprises of complete market value and forecast for the following countries and regions:

North America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast
  • U.S.
  • Canada
Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast
  • UK
  • Germany
  • France
  • Rest of Europe
Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Snapshot
          2.1.1. Global Gastrointestinal Stromal Tumor (GIST) Drug Market By Type,2019
               2.1.1.1.Amcasertib
               2.1.1.2.Anagrelide hydrochloride CR
               2.1.1.3.APG-1351
               2.1.1.4.Binimetinib
               2.1.1.5.Others
          2.1.2. Global Gastrointestinal Stromal Tumor (GIST) Drug Market By Application,2019
               2.1.2.1.Clinic
               2.1.2.2.Hospital
               2.1.2.3.Others
          2.1.3. Global Gastrointestinal Stromal Tumor (GIST) Drug Market By End-use,2019
          2.1.4. Global Gastrointestinal Stromal Tumor (GIST) Drug Market By Geography,2019

3. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028

5. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028

6. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Gastrointestinal Stromal Tumor (GIST) Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Gastrointestinal Stromal Tumor (GIST) Drug Providers
        8.4.1 Ariad Pharmaceuticals, Inc.
                8.1.1 Business Description
                8.1.2 Ariad Pharmaceuticals, Inc. Geographic Operations
                8.1.3 Ariad Pharmaceuticals, Inc. Financial Information
                8.1.4 Ariad Pharmaceuticals, Inc. Product Positions/Portfolio
                8.1.5 Ariad Pharmaceuticals, Inc. Key Developments
        8.4.2 Arog Pharmaceuticals, Inc.
                8.2.1 Business Description
                8.2.2 Arog Pharmaceuticals, Inc. Geographic Operations
                8.2.3 Arog Pharmaceuticals, Inc. Financial Information
                8.2.4 Arog Pharmaceuticals, Inc. Product Positions/Portfolio
                8.2.5 Arog Pharmaceuticals, Inc. Key Developments
        8.4.3 Array BioPharma Inc.
                8.3.1 Business Description
                8.3.2 Array BioPharma Inc. Geographic Operations
                8.3.3 Array BioPharma Inc. Financial Information
                8.3.4 Array BioPharma Inc. Product Positions/Portfolio
                8.3.5 Array BioPharma Inc. Key Developments
        8.4.4 Astex Pharmaceuticals, Inc.
                8.4.1 Business Description
                8.4.2 Astex Pharmaceuticals, Inc. Geographic Operations
                8.4.3 Astex Pharmaceuticals, Inc. Financial Information
                8.4.4 Astex Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.5 Astex Pharmaceuticals, Inc. Key Developments
        8.4.5 Blueprint Medicines Corporation
                8.5.1 Business Description
                8.5.2 Blueprint Medicines Corporation Geographic Operations
                8.5.3 Blueprint Medicines Corporation Financial Information
                8.5.4 Blueprint Medicines Corporation Product Positions/Portfolio
                8.5.5 Blueprint Medicines Corporation Key Developments
        8.4.6 Boston Biomedical, Inc.
                8.6.1 Business Description
                8.6.2 Boston Biomedical, Inc. Geographic Operations
                8.6.3 Boston Biomedical, Inc. Financial Information
                8.6.4 Boston Biomedical, Inc. Product Positions/Portfolio
                8.6.5 Boston Biomedical, Inc. Key Developments
        8.4.7 Calithera Biosciences, Inc.
                8.7.1 Business Description
                8.7.2 Calithera Biosciences, Inc. Geographic Operations
                8.7.3 Calithera Biosciences, Inc. Financial Information
                8.7.4 Calithera Biosciences, Inc. Product Positions/Portfolio
                8.7.5 Calithera Biosciences, Inc. Key Developments
        8.4.8 Chipscreen Biosciences Ltd
                8.8.1 Business Description
                8.8.2 Chipscreen Biosciences Ltd Geographic Operations
                8.8.3 Chipscreen Biosciences Ltd Financial Information
                8.8.4 Chipscreen Biosciences Ltd Product Positions/Portfolio
                8.8.5 Chipscreen Biosciences Ltd Key Developments
        8.4.9 Deciphera Pharmaceuticals, LLC
                8.9.1 Business Description
                8.9.2 Deciphera Pharmaceuticals, LLC Geographic Operations
                8.9.3 Deciphera Pharmaceuticals, LLC Financial Information
                8.9.4 Deciphera Pharmaceuticals, LLC Product Positions/Portfolio
                8.9.5 Deciphera Pharmaceuticals, LLC Key Developments
        8.4.10 F. Hoffmann-La Roche Ltd.
                8.10.1 Business Description
                8.10.2 F. Hoffmann-La Roche Ltd. Geographic Operations
                8.10.3 F. Hoffmann-La Roche Ltd. Financial Information
                8.10.4 F. Hoffmann-La Roche Ltd. Product Positions/Portfolio
                8.10.5 F. Hoffmann-La Roche Ltd. Key Developments
        8.4.11 Horizon Pharma Plc
                8.11.1 Business Description
                8.11.2 Horizon Pharma Plc Geographic Operations
                8.11.3 Horizon Pharma Plc Financial Information
                8.11.4 Horizon Pharma Plc Product Positions/Portfolio
                8.11.5 Horizon Pharma Plc Key Developments
        8.4.12 Immunicum AB
                8.12.1 Business Description
                8.12.2 Immunicum AB Geographic Operations
                8.12.3 Immunicum AB Financial Information
                8.12.4 Immunicum AB Product Positions/Portfolio
                8.12.5 Immunicum AB Key Developments
        8.4.13 Jiangsu Hengrui Medicine Co., Ltd.
                8.13.1 Business Description
                8.13.2 Jiangsu Hengrui Medicine Co., Ltd. Geographic Operations
                8.13.3 Jiangsu Hengrui Medicine Co., Ltd. Financial Information
                8.13.4 Jiangsu Hengrui Medicine Co., Ltd. Product Positions/Portfolio
                8.13.5 Jiangsu Hengrui Medicine Co., Ltd. Key Developments
        8.4.14 Kolltan Pharmaceuticals, Inc.
                8.14.1 Business Description
                8.14.2 Kolltan Pharmaceuticals, Inc. Geographic Operations
                8.14.3 Kolltan Pharmaceuticals, Inc. Financial Information
                8.14.4 Kolltan Pharmaceuticals, Inc. Product Positions/Portfolio
                8.14.5 Kolltan Pharmaceuticals, Inc. Key Developments
        8.4.15 Natco Pharma Limited
                8.15.1 Business Description
                8.15.2 Natco Pharma Limited Geographic Operations
                8.15.3 Natco Pharma Limited Financial Information
                8.15.4 Natco Pharma Limited Product Positions/Portfolio
                8.15.5 Natco Pharma Limited Key Developments
        8.4.16 Nerviano Medical Sciences S.r.l.
                8.16.1 Business Description
                8.16.2 Nerviano Medical Sciences S.r.l. Geographic Operations
                8.16.3 Nerviano Medical Sciences S.r.l. Financial Information
                8.16.4 Nerviano Medical Sciences S.r.l. Product Positions/Portfolio
                8.16.5 Nerviano Medical Sciences S.r.l. Key Developments
        8.4.17 Novartis AG
                8.17.1 Business Description
                8.17.2 Novartis AG Geographic Operations
                8.17.3 Novartis AG Financial Information
                8.17.4 Novartis AG Product Positions/Portfolio
                8.17.5 Novartis AG Key Developments
        8.4.18 Omeros Corporation
                8.18.1 Business Description
                8.18.2 Omeros Corporation Geographic Operations
                8.18.3 Omeros Corporation Financial Information
                8.18.4 Omeros Corporation Product Positions/Portfolio
                8.18.5 Omeros Corporation Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Gastrointestinal Stromal Tumor (GIST) Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Gastrointestinal Stromal Tumor (GIST) Drug: Market Segmentation 
FIG. 2 Global Gastrointestinal Stromal Tumor (GIST) Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Gastrointestinal Stromal Tumor (GIST) Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Gastrointestinal Stromal Tumor (GIST) Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Gastrointestinal Stromal Tumor (GIST) Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Gastrointestinal Stromal Tumor (GIST) Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Gastrointestinal Stromal Tumor (GIST) Drug Providers, 2019
FIG. 11 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Gastrointestinal Stromal Tumor (GIST) Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Gastrointestinal Stromal Tumor (GIST) Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 
1718

2045

OUR CLIENT